MAP2K7 and cutaneous melanoma: Primary cutaneous melanomas that harbourthe mutation can respond to inhibitor treatments [146], like BRAF inhibitors, which include vemurafenib, dabrafenib, and encorafenib, and MEK inhibitors, like trametinib, binimetinib, and cobimetinib [147].